logo
Wolters Kluwer Updates Sentri7, Enhancing Pharmacy and Nursing Workflows

Wolters Kluwer Updates Sentri7, Enhancing Pharmacy and Nursing Workflows

Business Wire2 days ago

WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health today announced extensive updates to its Sentri7 ® Drug Diversion and Sentri7 ® Pharmacy solutions, reinforcing its commitment to innovation in medication safety, compliance, and patient care. These improvements further equip clinical teams with actionable, data-driven insights to streamline workflows for drug diversion and medication management, ultimately supporting better patient care.
'Our mission is to help healthcare organizations deliver safer, higher-quality care with solutions that optimize the workflows supporting patient care and compliance in today's demanding healthcare environment,' said Karen Kobelski, Vice President and General Manager of Clinical Surveillance Compliance & Data Solutions at Wolters Kluwer Health. " With our team's deep expertise in pharmacy, technology, and artificial intelligence, we're providing customers with critical insights and support to address challenges like medication management, drug diversion prevention, and the opioid crisis.'
Sentri7 Drug Diversion delivers improved workflows
The redesigned Sentri7 Drug Diversion solution introduces a more intuitive interface, enabling teams to detect and manage drug diversion threats with greater precision and efficiency. Healthcare organizations can now act faster and more effectively to mitigate risks, with features like:
User-friendly dashboard: Consolidates essential risk factors and actionable insights into a single, user-friendly interface to streamline diversion detection follow-up.
Refined HEAT™ scoring and trend analysis: Quickly identifies high-risk staff across multiple facilities with a Watch List that improves alert monitoring of priority areas of concern.
Missing medication analysis: Saves time for busy nursing teams by reconciling medication transactions across care areas, enabling timely interventions.
'Sentri7 Drug Diversion has a very mature user interface. It is very straightforward. It is easy to use and train our diversion staff to use. The graphics are very clear to understand. The solution has a HEAT score that it gives when it suspects an employee of diversion. It promotes that information to us and tells us where there is suspicious activity rather than us having to look at the numbers and determine that on our own,' according to a pharmacy manager interviewed by KLAS Research, February 2025.
Sentri7 Pharmacy updates support patient-centered care
The updated Sentri7 Pharmacy solution delivers an efficient, patient-centric workflow to optimize medication therapies, safety and overall cost savings. Key updates include:
User-friendly interface: Tailored to support rounding workflows for individual patients, in addition to managing targeted medication surveillance across the entire patient population.
Enhanced documentation tools: Simplified and standardized data entry enhances reporting, enabling pharmacy teams to demonstrate impact with evidence-based metrics.
Actionable Performance Insights: Provides clear key performance indicators on cost savings, departmental contributions, and patient outcomes.
When asked about Wolters Kluwer's surveillance solution, one pharmacy analyst noted in a KLAS Research April 2025 interview, 'Wolters Kluwer is super engaging and allows for a lot of collaborative work with organizations. The vendor does a good job of meeting organizations where they are at and working toward solutions. Wolters Kluwer has just been great at engaging with end users on how to improve their Sentri7 Pharmacy Surveillance product. I would definitely recommend Sentri7 Pharmacy Surveillance.'
Learn more about the enhanced Sentri7 solutions.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vestis Corporation (VSTS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Vestis Corporation (VSTS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire

time17 minutes ago

  • Business Wire

Vestis Corporation (VSTS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Vestis Corporation ('Vestis' or the 'Company') (NYSE: VSTS) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VESTIS CORPORATION (VSTS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 7, 2025, Vestis released its second quarter fiscal 2025 financial results and revised its prior growth and revenue guidance for 2025, providing guidance for the third quarter, falling significantly below market expectations. The Company explained that the poor results were partially due to 'lost business in excess of new business' but primarily on 'lower adds over stops, which is how [it] describe[s] volumes changes with [its] existing customers.' On this news, Vestis's stock price fell $3.27, or 37.5%, to close at $5.44 per share on May 7, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Vestis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Sable Offshore Corp. (SOC) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Sable Offshore Corp. (SOC) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire

time24 minutes ago

  • Business Wire

Sable Offshore Corp. (SOC) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Sable Offshore Corp. ('Sable' or the 'Company') (NYSE: SOC) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SABLE OFFSHORE CORP. (SOC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 19, 2025, Sable announced that it had resumed oil production from one of three offshore platforms related for its Las Flores pipelines ('Onshore Pipeline') in California. Then, on May 23, 2025, the California State Land Commission sent Sable a letter regarding its May 19th announcement, warning that it 'appears to mischaracterize the nature of recent activities, causing significant public confusion and raising questions regarding Sable's intentions,' and that Sable had conflated offshore well testing activities required by a federal regulatory agency with the restart of operations. Then, on May 28, 2025, the Santa Barbara County Superior Court approved a preliminary injunction from the California Coastal Commission regarding Sable's maintenance and repair work in the coastal zone related to the Onshore Pipeline. On this news, Sable's stock price fell $5.04, or 15.3%, to close at $27.89 per share on May 28, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Sable securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

KBRA Assigns Preliminary Ratings to CROSS 2025-H5 Mortgage Trust
KBRA Assigns Preliminary Ratings to CROSS 2025-H5 Mortgage Trust

Business Wire

time28 minutes ago

  • Business Wire

KBRA Assigns Preliminary Ratings to CROSS 2025-H5 Mortgage Trust

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to ten classes of mortgage pass-through certificates from CROSS 2025-H5 Mortgage Trust, an RMBS transaction issued under the CROSS shelf, where Hildene in affiliation with CrossCountry Mortgage and CrossCountry Capital sponsored the transaction. The $416.5 million transaction is collateralized by a pool of 881 residential mortgages originated by CCM, including a meaningful concentration of collateral that KBRA considers to be 'non-prime', with fixed-rate mortgages (FRMs) and hybrid adjustable-rate mortgages (ARMs) making up 86.7% and 13.3% of the pool, respectively. KBRA's rating approach incorporated loan-level analysis of the mortgage pool through its Residential Asset Loss Model (REALM), an examination of the results from third-party loan file due diligence, cash flow modeling analysis of the transaction's payment structure, reviews of key transaction parties and an assessment of the transaction's legal structure and documentation. This analysis is further described in our U.S. RMBS Rating Methodology. To access ratings and relevant documents, click here. Click here to view the report. Recent Publications Methodologies Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1009870

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store